Return to homepagePandemic Pact

Monoclonal antibody therapy of COVID-19

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85467

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $410,149.86

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Research Location

    Australia

  • Lead Research Institution

    Garvan Institute of Medical Research

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

The 2019/20 coronavirus (COVID-19) outbreak originating in the Wuhan province of China represents a major health emergency. In the earlier 2003 outbreak protective antibodies against the highly related SARS coronavirus have been described. Intriguingly, recent data indicate that these antibodies may not only be applicable to SARS, but also to COVID-19. Here we outline a strategy to develop these antibodies for COVID-19 therapy.